Novo Nordisk indgår aftale med Trump om lavere priser på vægttabsmedicin
7/11 06:48
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026 Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channel […]...